Kirsten Minden1. 1. Children's University Hospital Charité Berlin and Epidemiology Unit, German Rheumatism Research Centre, Berlin DE-13353, Germany. minden@drfz.de
Abstract
BACKGROUND: Knowledge of the long-term outcomes of patients with juvenile idiopathic arthritis (JIA) has evolved during the past decade. Recent studies, using standardized classification criteria, new and reliable outcome measures and improved methods of statistical analyses, show that outcomes are still less than ideal. Approximately half of all young adults with JIA have ongoing active disease and over one third experience detectable degrees of disability and organ damage. These patients also show a distinctive pattern of growth disturbances. Most patients with general growth failure have systemic or polyarticular disease: significant short stature (final height standard deviation score <-2) has been noted in 41% of patients with systemic JIA and in 11% of patients with polyarticular JIA. In contrast, localized growth disturbances can be seen in patients with oligoarthritis. CONCLUSIONS: Despite its name, JIA can be a lifelong disorder. With early and more widespread use of biological and other innovative therapies, however, outcomes for patients with JIA should improve further. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: Knowledge of the long-term outcomes of patients with juvenile idiopathic arthritis (JIA) has evolved during the past decade. Recent studies, using standardized classification criteria, new and reliable outcome measures and improved methods of statistical analyses, show that outcomes are still less than ideal. Approximately half of all young adults with JIA have ongoing active disease and over one third experience detectable degrees of disability and organ damage. These patients also show a distinctive pattern of growth disturbances. Most patients with general growth failure have systemic or polyarticular disease: significant short stature (final height standard deviation score <-2) has been noted in 41% of patients with systemic JIA and in 11% of patients with polyarticular JIA. In contrast, localized growth disturbances can be seen in patients with oligoarthritis. CONCLUSIONS: Despite its name, JIA can be a lifelong disorder. With early and more widespread use of biological and other innovative therapies, however, outcomes for patients with JIA should improve further. Copyright 2009 S. Karger AG, Basel.
Authors: Philomine A van Pelt; Tim Takken; Marco van Brussel; Mirjam de Witte; Aike A Kruize; Nico M Wulffraat Journal: Pediatr Rheumatol Online J Date: 2012-08-20 Impact factor: 3.054
Authors: Philomien A van Pelt; Tim Takken; Marco van Brussel; Inge de Witte; Aike A Kruize; Nico M Wulffraat Journal: Pediatr Rheumatol Online J Date: 2012-08-27 Impact factor: 3.054